HIGHLIGHTS
- who: Daniel P. Petrylak from the University of Miami Health System, United States have published the research: What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib, in the Journal: (JOURNAL)
- what: The authors report a case study of a patient enrolled in TRITON2 based on next-generation sequencing (NGS) of an archival biopsy with subsequent investigation of pretreatment plasma cfDNA that revealed additional alterations of interest which the authors believe to have contributed to the patient's clinical . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.